Behavioural Effects of Basal Ganglia Rho-kinase Inhibition in the Unilateral 6-hydroxydopamine Rat Model of Parkinson's Disease

Overview

Journal Metab Brain Dis

Publisher Springer

Specialties Endocrinology
Neurology

Date 2016 Mar 22

PMID 26996632

Citations 3

Authors

Salim Yalcin Inan

Burak Cem Soner

Ayse Saide Sahin

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative disorders, which affects more than six million people in the world. While current available pharmacological therapies for PD in the early stages of the disease usually improve motor symptoms, they cause side effects, such as fluctuations and dyskinesias in the later stages. In this later stage, high frequency deep brain stimulation of the subthalamic nucleus (STN-DBS) is a treatment option which is most successful to treat drug resistant advanced PD. It has previously been demonstrated that activation of Rho/Rho-kinase pathway is involved in the dopaminergic cell degeneration which is one of the main characteristics of PD pathology. In addition, the involvement of this pathway has been suggested in diverse cellular events in the central nervous system; such as epilepsy, anxiety-related behaviors, regulation of dendritic and axonal morphology, antinociception, subarachnoid haemorrhage, spinal cord injury and amyotrophic lateral sclerosis. However, up to date, to our knowledge there are no previous reports showing the beneficial effects of the potent Rho-kinase inhibitor Y-27632 in the 6-hydroxydopamine (6-OHDA) rat model of PD. Therefore, in the present study, we investigated the behavioural effects of basal ganglia Y-27632 microinjections in this PD model. Our results indicated that basal ganglia Y-27632 microinjections significantly decreased the number of contralateral rotations-induced by apomorphine, significantly increased line crossings in the open-field test, contralateral forelimb use in the limb-use asymmetry test and contralateral tape playing time in the somatosensory asymmetry test, which may suggest that Y-27632 could be a potentially active antiparkinsonian agent.

Citing Articles

The Sirtuin 2 Inhibitor AK-7 Leads to an Antidepressant-Like Effect in Mice via Upregulation of CREB1, BDNF, and NTRK2 Pathways.

Guclu E, Inan S, Vural H Mol Neurobiol. 2022; 59(11):7036-7044.

PMID: 36074231 DOI: 10.1007/s12035-022-03026-8.

Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities.

Zamboni V, Jones R, Umbach A, Ammoni A, Passafaro M, Hirsch E Int J Mol Sci. 2018; 19(6).

PMID: 29925821 PMC: 6032284. DOI: 10.3390/ijms19061821.

Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.

Antipova V, Holzmann C, Schmitt O, Wree A, Hawlitschka A Front Behav Neurosci. 2017; 11:119.

PMID: 28680396 PMC: 5478737. DOI: 10.3389/fnbeh.2017.00119.

References

Sanchez M, Gastaldi L, Remedi M, Caceres A, Landa C . Rotenone-induced toxicity is mediated by Rho-GTPases in hippocampal neurons. Toxicol Sci. 2008; 104(2):352-61. DOI: 10.1093/toxsci/kfn092. View

Tonges L, Frank T, Tatenhorst L, Saal K, Koch J, Szego E . Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain. 2012; 135(Pt 11):3355-70. PMC: 3501973. DOI: 10.1093/brain/aws254. View

Li M, Huang Y, Ma A, Lin E, Diamond M . Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol Dis. 2009; 36(3):413-20. DOI: 10.1016/j.nbd.2009.06.011. View

Blandini F, Armentero M, Martignoni E . The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord. 2008; 14 Suppl 2:S124-9. DOI: 10.1016/j.parkreldis.2008.04.015. View

Kucuk A, Golgeli A, Saraymen R, Koc N . Effects of age and anxiety on learning and memory. Behav Brain Res. 2008; 195(1):147-52. DOI: 10.1016/j.bbr.2008.05.023. View

Narita M, Takagi M, Aoki K, Kuzumaki N, Suzuki T . Implication of Rho-associated kinase in the elevation of extracellular dopamine levels and its related behaviors induced by methamphetamine in rats. J Neurochem. 2003; 86(2):273-82. DOI: 10.1046/j.1471-4159.2003.01784.x. View

Ito K, Hirooka Y, Hori N, Kimura Y, Sagara Y, Shimokawa H . Inhibition of rho-kinase in the nucleus tractus solitarius enhances glutamate sensitivity in rats. Hypertension. 2005; 46(2):360-5. DOI: 10.1161/01.HYP.00001747119.23178.05. View

Schwarting R, Huston J . The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol. 1996; 50(2-3):275-331. DOI: 10.1016/s0301-0082(96)00040-8. View

Connolly B, Lang A . Pharmacological treatment of Parkinson disease: a review. JAMA. 2014; 311(16):1670-83. DOI: 10.1001/jama.2014.3654. View

10.

Dubreuil C, Marklund N, Deschamps K, McIntosh T, McKerracher L . Activation of Rho after traumatic brain injury and seizure in rats. Exp Neurol. 2006; 198(2):361-9. DOI: 10.1016/j.expneurol.2005.12.002. View

11.

Rodriguez-Perez A, Dominguez-Meijide A, Lanciego J, Guerra M, Labandeira-Garcia J . Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol Dis. 2013; 58:209-19. DOI: 10.1016/j.nbd.2013.06.004. View

12.

Mueller B, Mack H, Teusch N . Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005; 4(5):387-98. DOI: 10.1038/nrd1719. View

13.

Dash P, Orsi S, Moody M, Moore A . A role for hippocampal Rho-ROCK pathway in long-term spatial memory. Biochem Biophys Res Commun. 2004; 322(3):893-8. DOI: 10.1016/j.bbrc.2004.08.004. View

14.

Loirand G, Sauzeau V, Pacaud P . Small G proteins in the cardiovascular system: physiological and pathological aspects. Physiol Rev. 2013; 93(4):1659-720. DOI: 10.1152/physrev.00021.2012. View

15.

Sughrue M, Mocco J, Komotar R, Mehra A, DAmbrosio A, Grobelny B . An improved test of neurological dysfunction following transient focal cerebral ischemia in rats. J Neurosci Methods. 2006; 151(2):83-9. DOI: 10.1016/j.jneumeth.2005.04.023. View

16.

Wirth A . Rho kinase and hypertension. Biochim Biophys Acta. 2010; 1802(12):1276-84. DOI: 10.1016/j.bbadis.2010.05.002. View

17.

Buyukafsar K, Yalcin I, Kurt A, Tiftik R, Sahan-Firat S, Aksu F . Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice. Eur J Pharmacol. 2006; 541(1-2):49-52. DOI: 10.1016/j.ejphar.2006.04.042. View

18.

Geiger B, Frank L, Caldera-Siu A, Pothos E . Survivable stereotaxic surgery in rodents. J Vis Exp. 2008; (20). PMC: 3233859. DOI: 10.3791/880. View

19.

Deumens R, Blokland A, Prickaerts J . Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 2002; 175(2):303-17. DOI: 10.1006/exnr.2002.7891. View

20.

Benabid A, Chabardes S, Mitrofanis J, Pollak P . Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol. 2008; 8(1):67-81. DOI: 10.1016/S1474-4422(08)70291-6. View